M
MRVI
Maravai Lifesciences Holdings, I…
2.35
-0.01-0.21%Opening15:06 09/04 EDT
OPEN/PREV CLOSE2.360/2.360
TODAY RANGE2.300-2.380
VOL259.12K
MARKET CAP601.38M
52 WEEK RANGE1.665-9.60
AVG VOL (3M)1.62M
% TURNOVER0.10%
TURNOVER--
P/E (TTM)-1.7225
% RANGE3.41%
EPS(TTM)-1.3672
P/E(FORWARD)-3.3169
P/B2.261
BVPS1.041
DIVIDEND--
P/S2.296
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP256.01M
SHARES OUTSTANDING255.36M
NEXT EARNINGS11/05-11/10
FREE FLOAT108.71M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·08/14 11:15
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price
Dow Jones·08/12 17:55
Maravai LifeSciences Shares Rise After Restructuring, Layoffs
Dow Jones·08/12 14:16
Maravai LifeSciences Is Maintained at Outperform by RBC Capital
Dow Jones·08/12 14:16
Maravai LifeSciences Price Target Cut to $5.00/Share From $7.00 by RBC Capital
TipRanks·08/12 13:15
Maravai Lifesciences price target lowered to $5 from $7 at RBC Capital
TipRanks·08/12 13:10
Maravai Lifesciences price target lowered to $5 from $10 at Craig-Hallum
TipRanks·08/12 11:56
Stifel Nicolaus Keeps Their Buy Rating on Maravai Lifesciences Holdings (MRVI)
TipRanks·08/12 11:46
Maravai Lifesciences Holdings (MRVI) Gets a Hold from Guggenheim
TipRanks·08/12 10:57
RBC Capital Keeps Their Buy Rating on Maravai Lifesciences Holdings (MRVI)
TipRanks·08/12 09:56
Maravai Lifesciences: Strategic Shift Amid Mixed Results Warrants Hold Rating
TipRanks·08/12 04:09
Maravai LifeSciences Announces Restructuring Amid Revenue Decline
Seeking Alpha·08/12 03:36
Maravai signals $50M annualized cost reduction plan as leadership targets positive EBITDA in 2026
Dow Jones·08/11 21:31
Maravai Life Sciences Cuts 25% of Workforce
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.